These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 23600839)

  • 1. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.
    Yasuda S; Sho M; Yamato I; Yoshiji H; Wakatsuki K; Nishiwada S; Yagita H; Nakajima Y
    Clin Exp Immunol; 2013 Jun; 172(3):500-6. PubMed ID: 23600839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
    Shigeta K; Datta M; Hato T; Kitahara S; Chen IX; Matsui A; Kikuchi H; Mamessier E; Aoki S; Ramjiawan RR; Ochiai H; Bardeesy N; Huang P; Cobbold M; Zhu AX; Jain RK; Duda DG
    Hepatology; 2020 Apr; 71(4):1247-1261. PubMed ID: 31378984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apatinib potentiates the therapeutic effect of anti-PD-1 in locally advanced head and neck cancers.
    Liu S; Zhang L; Ye W; Zhou R; Gu Z; Shi C; Xu S; Li J; Zhang Z; Han Y
    Oral Dis; 2024 Jul; 30(5):2940-2951. PubMed ID: 37846172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Blockade of GARP:TGF-β1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP
    Bertrand C; Van Meerbeeck P; de Streel G; Vaherto-Bleeckx N; Benhaddi F; Rouaud L; Noël A; Coulie PG; van Baren N; Lucas S
    Front Immunol; 2021; 12():704050. PubMed ID: 34386010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
    Gao F; Yang C
    Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
    Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
    Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
    Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
    Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
    Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
    Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
    Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.